Understanding how dengue vaccination leads to long-lasting immunity
Official title: Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population
Funded at University of Rhode Island · NIH-11051162 · Data updated 2026-11-12
This study is looking at how well a dengue vaccine works in the long run by checking blood samples from people who have already taken the vaccine, to find out what helps keep their immunity strong over time.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rhode Island NIH-funded |
| Lab location | 1 site (Kingston, United States) |
| Project start | March 6, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $567,169 |
| NIH project number | 5U01AI179523-02 |
| Project ID | NIH-11051162 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received the dengue vaccine and are part of a dengue-endemic population.
✕Less likely to help
Patients who have not been vaccinated against dengue or those living in non-endemic regions may not benefit from this research.
What this research studies
This research investigates the immune responses generated by a dengue vaccine to determine what factors contribute to long-lasting immunity. By analyzing blood samples from participants in previous dengue vaccine trials, the study aims to identify specific immune cell responses and genetic profiles that correlate with durable protection against the virus. The research focuses on both T and B lymphocytes, which are crucial for the immune response, to uncover the mechanisms that lead to sustained antibody levels after vaccination.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of dengue vaccines by identifying ways to promote long-lasting immunity in vaccinated individuals.
How similar studies have gone: Previous research has shown promising results in understanding vaccine-induced immunity, but this specific approach focusing on dengue vaccination is relatively novel.
Where this research is happening
-
University of Rhode Island
Kingston, United States Active
Researchers
- Principal investigator: Rothman, Alan L — University of Rhode Island
- Study coordinator: Rothman, Alan L
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
How the immune system responds to dengue vaccines and infection
This project compares immune reactions in people given different dengue vaccine formulations to find why one vaccine fully prevented DENV-2 infection while another did not.
-
How prior dengue infections shape T cell responses after a new infection or vaccine
This project looks at how a person’s existing dengue immunity affects their body's T cell response when exposed to a different dengue serotype or a live dengue vaccine, with a focus on kids and how this influences protection and safety.
-
Protective immunity after dengue infections and vaccination
Researchers are studying how our immune system remembers dengue and how vaccines influence that protection, aiming to spot clues that predict who remains protected or at risk after infection or vaccination.
-
Dengue vaccine-B cell and T cell responses linked to protection after controlled dengue infection
A Johns Hopkins-led study will look at how the body’s B and T cells respond to dengue vaccines and how these responses relate to protection against dengue infection in people who participate in a controlled infection model.
-
How long dengue vaccine protection lasts in areas where dengue is common
This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.